Officer and Director Stock Transactions

Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics, Inc., reported a series of stock transactions on April 9, 2026. These transactions were executed under a Rule 10b5-1 trading plan. Malcom acquired 2,170 shares of Common Stock at $16.00 per share and disposed of 2,170 shares of Common Stock at $27.38 per share. Additionally, he disposed of a stock option for 2,170 shares, with the option having an exercise price of $16.00. Following these transactions, Malcom holds 78,310 shares of Common Stock directly. The stock option vested over time, with 25% vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. The option expiration date is February 9, 2033.